A neurologist's personal battle against Alzheimer's disease
Abnormal tau protein is found in the neurofibrillary tangles found in nerve cells in the brain starting a few years before the onset of cognitive impairment in Alzheimer’s disease. Most drug trials attempting to...
Increasing evidence has shown that getting too little sleep increases the risk of developing dementia. In one recent study those routinely getting 6 or less hours of sleep had a significantly greater chance of developing...
Now that Aduhelm (aducanumab) has been approved by the FDA for people with early-stage Alzheimer’s, those with mild cognitive impairment or mild dementia, who will be responsible for the $56,000 annual price tag? A...
A recurring theme of my blog has been that our best shot at attacking Alzheimer’s disease is in the earliest stage, before cognitive impairment has started. We now know that the first pathological signs...
Yesterday I came across an interesting paper from 2013 in Lancet Neurology that adds important information about the case of Auguste D, the first patient diagnosed with what was later called Alzheimer’s disease. I mentioned this...
As reported in the New York Times today, two prominent American medical institutions, the Cleveland Clinic and the Mt. Sinai Health System in New York, have announced that they will not allow administration of...
Today Biogen announced the changes highlighted in yellow below in the prescribing information for Aduhelm, recently approved for treatment of Alzheimer’s disease. There were several problems with the FDA’s initial brand label authorizing use...
I read Lisa Genova’s first book, Still Alice, in 2009, long before I had any inkling that I was on the path to Alzheimer’s. I was busy in my practice as a general neurologist, and...
When donepezil (Aricept) was approved in 1996, it was the first tolerable drug available to treat the cognitive symptoms of Alzheimer’s disease. I remember being shocked that the price was so high, about $120...
Yesterday I participated in a panel discussion regarding recommendations for use of aducanumab, now called by the proprietary name Aduhelm, in the treatment of Alzheimer’s disease. The conference, Dialogue: Current Perspectives on Aducanumab, was sponsored...
Recent Comments